Pulsatile Drug Delivery Systems: A Comprehensive Review of Chronotherapeutic Paradigms

Traditional drug delivery focuses on maintaining constant plasma concentrations. However, many chronic ailments follow a biological clock. Chronopharmaceutics is the branch of pharmacy that addresses the metabolic and physiological changes occurring within a 24-hour cycle. PDDS is the primary tool of this discipline, ensuring that drug concentration is highest when the disease symptoms are most severe.

Pulsatile Drug Delivery Systems (PDDS) represent a chronotherapeutic approach designed to release a specific drug payload rapidly and completely after a predetermined lag time, synchronized with the body’s natural circadian rhythms. Unlike conventional sustained-release forms, PDDS address the temporal needs of diseases like nocturnal asthma, hypertension, and rheumatoid arthritis, where symptoms peak at specific hours. These systems are categorized into time-controlled (e.g., Pulsincap™), stimuli-induced (e.g., pH or enzyme-responsive), and externally regulated platforms. By aligning peak plasma concentrations with peak physiological requirements, PDDS enhance therapeutic efficacy, minimize side effects, and improve patient compliance, utilizing advanced technologies such as osmotic pumps, rupturable coatings, and emerging 3D-printed personalized dosage forms.

Fig.No:1. Comparison of Plasma Concentration Profiles

2. BIOLOGICAL RATIONALE: CIRCADIAN RHYTHMS AND DISEASE:

• The human body is governed by a circadian rhythm—a 24-hour cycle of biological activity. The effectiveness of certain drugs varies significantly based on the timing of administration.
• The biological rationale for Pulsatile Drug Delivery Systems (PDDS) is rooted in chronobiology, which demonstrates that many disease states do not maintain constant activity but rather follow the body's internal 24-hour circadian rhythm.
• These rhythms, governed by the master pacemaker in the suprachiasmatic nucleus, influence various physiological processes including blood pressure, gastric acid secretion, and airway resistance.
• Consequently, many chronic conditions exhibit predictable nocturnal or early-morning exacerbations—such as the "morning surge" in blood pressure increasing the risk of stroke, or the nighttime trough in cortisol levels triggering asthma attacks.
• By utilizing PDDS to create a programmed lag time, medication can be administered at bedtime to achieve peak plasma concentrations precisely when these clinical symptoms are at their most severe, thereby maximizing therapeutic efficacy while minimizing systemic side effects during periods of low disease activity.

Fig.No:2. Circadian Patterns of Chronic Diseases

1. Cardiovascular Conditions: Myocardial infarction and stroke are more frequent in the early morning (6:00 AM – 10:00 AM) due to surges in blood pressure and heart rate.
2. Nocturnal Asthma: Airway resistance peaks at night (2:00 AM – 4:00 AM), leading to "morning dipping."
3. Peptic Ulcers: Gastric acid secretion is maximal in the late evening.
4. Arthritis: Rheumatoid arthritis patients experience peak stiffness and pain in the morning, while Osteoarthritis pain often worsens in the evening.

3. CLASSIFICATION OF PULSATILE SYSTEMS:

3.1 Time-Controlled Systems:

• These systems utilize internal mechanisms to trigger release after a specific lag phase.

1. Capsular Systems: The most iconic example is the Pulsincap™. It consists of an insoluble capsule body containing the drug, sealed with a swellable hydrogel plug. Upon contact with water, the plug swells and, after a set time, is ejected, allowing the drug to release rapidly.
2. Rupturable Systems: The drug core is coated with an insoluble but water-permeable polymer (like Ethyl cellulose). Water enters the core, creating internal pressure (osmotic or swelling) until the coating ruptures.

Fig.No:3. Schematic of a reservoir-type pulsatile system

3. Erodible/Soluble Coatings: Layers of soluble polymers (like HPMC or Pectin) dissolve  slowly in the GIT. Once the coating is gone, the drug pulse occurs.

Fig.No:4. Internal mechanism of the Pulsincap™ device.

3.2 Stimuli-Induced Systems:

• These systems rely on environmental triggers within the body to initiate release.

1. pH-Dependent Systems: Utilizing enteric polymers (Eudragit® L or S) that remain intact in the stomach (pH 1.2) but dissolve when they reach the higher pH of the small intestine (pH 6.8) or colon (pH 7.4).
2. Enzyme-Responsive Systems: Particularly useful for colon targeting. Polymers like Guar gum or Chitosan are degraded only by the microflora (enzymes) present in the large intestine.
3. Temperature-Responsive Systems: Hydrogels that undergo a phase transition at a specific temperature, releasing the drug only when the body temperature reaches a certain threshold (useful for fever-related triggers).

3.3 Externally Regulated Systems:

• These are active systems controlled from outside the body.

1. Magnetically Triggered: Incorporating magnetic particles into a polymer matrix. Application of an external magnetic field causes the drug to "squeeze" out.
2. Electro-Responsive: Utilizing conductive polymers that change porosity when an electrical pulse is applied.

4. DESIGN AND FORMULATION STRATEGIES:

• Designing a PDDS requires careful selection of:

1. Excipients: Swelling agents (Cross-povidone), Osmogens (NaCl), and specialized polymers.
2. Lag Time Determinants: Coating thickness, polymer viscosity, and orifice size in osmotic systems.
3. Dosage Form: Multiparticulate systems (pellets/beads) are often preferred over single-unit systems (tablets) as they provide more consistent gastric emptying and lower risk of dose dumping.
4. Standardization of Manufacturing Parameters: Critical process parameters (CPPs) such as spray rate during coating and the compression force of the core must be standardized, as even slight variations can cause significant shifts in the lag time.
5. Use of Bioadhesive Polymers: To prevent the dosage form from being excreted before the "pulse" occurs (especially for colon targeting), adding bioadhesive agents (like Carbopol) helps the system remain at the target absorption site during the lag phase.

5. MARKETED TECHNOLOGIES AND PROPRIETARY PLATFORMS:

Fig.No:5. Cross-section of the OROS® (Osmotic Release Oral System)